Free Trial

Astria Therapeutics Q3 2023 Earnings Report

Astria Therapeutics logo
$9.55 -0.12 (-1.24%)
(As of 12/17/2024 ET)

Astria Therapeutics EPS Results

Actual EPS
-$0.63
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

Astria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Astria Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

DeFi Coin on Verge of Breakout! (Ad)

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!

Astria Therapeutics Earnings Headlines

Astria Therapeutics price target raised to $32 from $28 at Oppenheimer
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
See More Astria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astria Therapeutics and other key companies, straight to your email.

About Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

View Astria Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings